ImmuCell (ICCC) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmuCell (ICCC) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 133.3% versus a loss of 67.4%. Over five years, ICCC leads with a +18.7% price change compared with -95.9% for IMDX. ImmuCell is the larger company by market cap ($99.3 million vs $80.9 million), about 1.2 times the size, while Insight Molecular Diagnostics is growing revenue faster (+115.6% vs +4.3%).
ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -1238.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | IMDX |
|---|---|---|
| Share price | $10.92 | $1.97 |
| Market cap | $99.28M | $80.88M |
| 1-day change | -2.41% | +18.67% |
| YTD return | +77.56% | -73.73% |
| 1-year return | +133.33% | -67.38% |
| 5-year return | +18.70% | -95.91% |
| P/E ratio (TTM) | 57.47 | — |
| EPS (TTM) | $0.19 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.64M | $4.05M |
| Revenue growth (YoY) | +4.34% | +115.58% |
| Net income (latest FY) | $-1.04M | $-50.22M |
| Gross margin | 41.40% | 56.67% |
| Operating margin | 5.97% | -1260.76% |
| Net margin | -3.76% | -1238.52% |
| 52-week high | $12.10 | $7.51 |
| 52-week low | $4.67 | $1.50 |
| Distance from 52-week high | -9.75% | -73.77% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +318.78% |
| Average volume | 13.44K | 261.88K |
| Shares outstanding | 9.09M | 41.05M |
| Employees | 73 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICCC has outperformed IMDX by 200.7 percentage points over the past year.
- ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -1238.5 cents for Insight Molecular Diagnostics.
- Insight Molecular Diagnostics grew revenue faster in its latest fiscal year (+115.58% vs +4.34%).
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
ICCC vs IMDX FAQ
Which is bigger, ImmuCell or Insight Molecular Diagnostics?
ImmuCell (ICCC) is larger, with a market capitalization of $99.28M compared with $80.88M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, ICCC or IMDX?
ICCC returned +133.33% over the past 12 months, compared with -67.38% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Insight Molecular Diagnostics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.